Surgery Partners director granted 11,670 shares

Surgery Partners, Inc. director Teresa DeLuca reported an acquisition of company common stock through an equity grant.

Rhea-AI Filing Summary

Surgery Partners, Inc. director Teresa DeLuca reported an acquisition of company common stock through an equity grant. On June 5, 2026, she received 11,670 shares of common stock at a reference price of $13.71 per share as a grant or award, not an open-market purchase. Following this grant, her directly held position increased to 56,843 shares of Surgery Partners common stock. According to a footnote, these granted shares are scheduled to vest on June 5, 2027, meaning they become fully earned over time rather than immediately.

Insider Trade Summary

Grant/Award: 11,670 shares

Grant/Award 1 txn

Insider DeLuca Teresa

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	11,670	$13.71	$160K

Holdings After Transaction: Common Stock — 56,843 shares (Direct)

Footnotes (1)

1. F1. Shares will vest on June 5, 2027.

Key Figures

Equity grant size: 11,670 shares Grant reference price: $13.71 per share Total holdings after grant: 56,843 shares +2 more

5 metrics

Equity grant size 11,670 shares Common Stock grant on June 5, 2026

Grant reference price $13.71 per share Price per share for the reported grant

Total holdings after grant 56,843 shares Direct ownership following the transaction

Vesting date June 5, 2027 Date when granted shares vest

Transaction code A Grant, award, or other acquisition

Key Terms

Common Stock, Grant, award, or other acquisition, vest, Form 4

4 terms

Common Stock financial

"security_title: "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Grant, award, or other acquisition financial

"transaction_code_description: "Grant, award, or other acquisition""

vest financial

"Shares will vest on June 5, 2027."

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

Form 4 regulatory

"INSIDER FILING DATA (Form 4):"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Teresa DeLuca report for SGRY?

Director Teresa DeLuca reported receiving 11,670 shares of Surgery Partners common stock as a grant or award on June 5, 2026. This is a compensation-related acquisition, not an open-market stock purchase or sale.

Was the SGRY insider transaction a stock purchase or a grant?

The transaction was a grant or award acquisition, coded "A" on Form 4. DeLuca did not buy these shares in the market; they were granted to her as part of her compensation, at a reference price of $13.71 per share.

How many SGRY shares does Teresa DeLuca hold after this Form 4 filing?

After the reported transaction, DeLuca directly holds 56,843 shares of Surgery Partners common stock. This total reflects her position following the grant of 11,670 shares reported on June 5, 2026 in the Form 4 filing.

When do the newly granted SGRY shares to Teresa DeLuca vest?

The footnote states that the 11,670 granted shares will vest on June 5, 2027. Vesting means the shares become fully earned and no longer subject to forfeiture conditions associated with the original equity award grant.

Does the SGRY Form 4 show any stock sales by Teresa DeLuca?

No stock sales are reported in this Form 4. The filing shows a single acquisition transaction via an equity grant of 11,670 common shares, with no corresponding dispositions, exercises, gifts, or tax-withholding entries listed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/09/2026 - 04:27 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

DeLuca Teresa

(Last) (First) (Middle)

C/O SURGERY PARTNERS, INC.

340 SEVEN SPRINGS WAY, SUITE 600

(Street)

BRENTWOOD TENNESSEE 37027

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Surgery Partners, Inc. [ SGRY ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/05/2026		A		11,670(1)	A	$13.71	56,843	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares will vest on June 5, 2027.

Remarks:

	/s/ Jennifer Baldock, Attorney-in-Fact	06/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)